|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results demonstrated that this novel polymorphism of the RET gene is associated with an increased risk of lung cancer in the Korean population.
|
20944145 |
2010 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest that heterodimers of MET with EGFR, HER2, HER3, or RET have differential roles in tumour development, and they provide new insight into the function of trans-phosphorylated RTKs as heterodimerisation partners of MET in lung cancer with MET amplification.
|
21847121 |
2011 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that a subset of NSCLCs could be caused by a fusion of KIF5B and RET, and suggest the chimeric oncogene as a promising molecular target for the personalized diagnosis and treatment of lung cancer.
|
22194472 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.
|
22327622 |
2012 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, patient-derived lung cancer cell lines harboring RET fusions have not yet been established or identified, and therefore, the effectiveness of an RET inhibitor on lung tumors with endogenous RET fusion has not yet been studied.
|
23154560 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The KIF5B-RET fusion defines an additional subset of lung cancer with a potentially targetable driver oncogene enriched in never smokers with "pan-negative" lung adenocarcinomas.
|
23052255 |
2012 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The RET/β actin mRNA levels were not significantly different between lung cancer (6.359 ± 15.268) and adjacent normal lung tissues (8.205 ± 28.931, P = 0.6332).
|
23342255 |
2012 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET fusion gene: translation to personalized lung cancer therapy.
|
23991695 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells.
|
23856031 |
2013 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
|
25384085 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We hypothesized that RET chromosomal rearrangement may represent a genetic mechanism of radiation-induced lung cancer.
|
24346100 |
2014 |
|
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Gain of copy number and amplification of the RET gene in lung cancer.
|
25303898 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
|
24418728 |
2014 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To verify the oncogenic activity of KIF5B-RET kinase in lung cancer cells, we manipulated its expression genetically followed by colony formation and tumor formation assays.
|
25047660 |
2014 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic fusion of the RET (rearranged during transfection) gene was recently identified as a novel driver gene aberration not only for the development of thyroid carcinoma but also of lung adenocarcinoma, the most frequent histological type of lung cancer.
|
25064355 |
2014 |
|
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decreased MARVELD1 level in lung cancer reduces NMD efficiency through diminishing the association between NMD complex component UPF1/SMG1 and premature termination codons containing mRNA (PTC-mRNA).
|
25520033 |
2014 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
As overlapping gene fusions involving actionable kinases are emerging in both IMT and lung cancer, we set out to evaluate abnormalities in ALK, ROS1, PDGFRB, NTRK1, and RET by fluorescence in situ hybridization.
|
25723109 |
2015 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the first bench-to-bedside evidence that RET inhibitor combined with an mTOR inhibitor is active against brain-metastatic RET-rearranged lung cancer and the first evidence of blood-brain barrier penetration.
|
25982012 |
2015 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, RET, and HER2 have been under development.
|
27686809 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The accrual of patients with RET-rearranged lung cancer to this protocol has been completed but the trial is still ongoing because several patients remain on active treatment.
|
27825636 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
|
26762747 |
2016 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RET rearrangements are targetable, oncogenic lung cancer drivers.
|
27056998 |
2016 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients.
|
28082048 |
2017 |
|
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
|
28181564 |
2017 |
|
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial cells, which are known to produce EGF, decreased the sensitivity of CCDC6-RET lung cancer cells to RET inhibitors, an effect that was inhibited by EGFR small interfering RNA (siRNA), anti-EGFR antibody (cetuximab), and EGFR-TKI (Iressa).
|
27873490 |
2017 |